Medpace (MEDP) came out with quarterly earnings of $3.20 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 30.61%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $2.23 per share when it actually produced earnings of $2.46, delivering a surprise of 10.31%.Over ...

Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com Medpace Holdings, Inc. Reports First Quarter 2024 Results CINCINNATI, OHIO, April 22, 2024-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Revenue for the three months ended March 31, 2024 increased 17.7% to $511.0 ...

Financial Data and Key Metrics Changes - Revenue for Q4 2023 was $498.4 million, representing a year-over-year increase of 26.5% and a full year revenue of $1.89 billion, a 29.2% increase from 2022 [37][38] - EBITDA for Q4 2023 was $95.8 million, up 19.2% from $80.4 million in Q4 2022, with a full year EBITDA of $362.5 million, a 17.7% increase from the prior year [31][66] - Net income for Q4 2023 was $78.3 million, a 14% increase compared to $68.7 million in the prior year, with full year net income of $282.8 million, a 15.3% increase from 2022 [66] Business Line Data and Key Metrics Changes - The company reported a net new business awards entering backlog in Q4 of $614.7 million, a 26.7% increase from the prior year, resulting in a net book-to-bill ratio of 1.23 [37] - Full year 2023 net new business awards were $2.36 billion, an increase of 28.8%, with an ending backlog of approximately $2.8 billion, a 20.2% increase from the prior year [37] Market Data and Key Metrics Changes - The company expects 2024 total revenue to be in the range of $2.15 billion to $2.2 billion, representing growth of 14% to 16.7% over 2023 [32] - The effective tax rate for 2024 is projected to be between 16% to 17%, with interest income expected at $18.4 million [32] Company Strategy and Development Direction - The company is optimistic about the funding environment and project progression, indicating a trend towards improvement after a volatile period [70] - The company plans to maintain a hiring growth rate of about 10% in 2024, aligning with expected revenue growth of approximately 15% [43] Management Comments on Operating Environment and Future Outlook - Management noted that cancellations are expected to remain within a normal range, with a projection of less than 4.5% for 2024 [26] - The company is seeing a clear direction in project starts and is optimistic about the business environment moving into 2024 [70] Other Important Information - The EBITDA margin for Q4 2023 was 19.2%, down from 20.4% in the prior year, impacted by higher reimbursable costs and personnel costs [31] - The company did not repurchase any shares during Q4 2023, with a total of approximately 781,000 shares repurchased for $144 million throughout the year [39] Q&A Session Summary Question: What is the outlook for headcount growth? - Management indicated a 10% growth in headcount for 2024, down from previous expectations of mid-teens growth, attributed to efficiencies and a more stable business environment [4] Question: What is driving the elevated level of pass-throughs? - Elevated pass-throughs are driven by inflationary costs at investigator sites and a mix of large Phase III studies, expected to remain elevated into 2024 [3] Question: How are cancellations tracking? - Cancellations are expected to stay within the usual range, indicating a more normalized level compared to previous years [26] Question: What is the outlook for EBITDA growth in 2024? - The company expects EBITDA to grow between 10.3% to 18.6% in 2024, despite not changing the revenue outlook [5] Question: How is the competition affecting share gains? - The company has been gaining market share, growing at a rate considerably above industry peers, with a win rate above long-term trends [7][21]

Financial Performance - The company reported a significant increase in revenue, achieving $1.5 billion for the fiscal year, representing a 20% year-over-year growth[10]. - The company reported a net income of $300 million, a 30% increase compared to the last fiscal year[10]. - Operating margins improved to 25%, up from 22% in the previous year, due to cost management strategies[10]. User Growth and Engagement - User data showed a 15% increase in active users, reaching 2 million by the end of the fiscal year[10]. - The company plans to increase its workforce by 10% to support growth initiatives and new product development[10]. Future Projections and Guidance - The company provided guidance for the next fiscal year, projecting revenue growth of 10% to 15%[10]. - New product launches are expected to contribute an additional $200 million in revenue over the next year[10]. - The company acknowledges the inherent uncertainty in projections and estimates of future performance[14]. Market Expansion and Strategy - Market expansion efforts include entering three new international markets, projected to increase market share by 5%[10]. - The company is exploring potential acquisitions to bolster its product offerings, with a budget of $100 million allocated for this purpose[10]. Research and Development - The company is investing $50 million in research and development for new technologies aimed at enhancing user experience[10]. Clinical Trials and Pharmaceutical Data - Phase I trials typically involve 20 to 100 subjects and focus on establishing safety and dosage[18]. - Phase II trials evaluate efficacy and safety in a few hundred patients over one to two years[19]. - Phase III trials assess the clinical product candidate in larger populations, lasting from one to four years, and are crucial for product approval[20]. - Phase IV trials monitor long-term risks and benefits of drugs, enrolling thousands of patients over several years[21]. - The report includes a glossary defining key terms related to the pharmaceutical industry[15][16][17]. Data Verification and Caution - The company emphasizes the importance of independent verification of market and industry data[14]. - Market data in the Annual Report is based on management's estimates and industry sources, with a caution against over-reliance on these estimates[13]. - The company defines large pharmaceutical companies as the top 20 by worldwide prescription drug sales, while mid-sized companies have at least $250 million in sales[15][16]. Communication with Investors - The company utilizes its website and social media channels for distributing material information to investors[11].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 _________ ...

Financial Data and Key Metrics Changes - Revenue for Q3 2023 was $492.5 million, representing a year-over-year increase of 28.3% [51] - Year-to-date revenue for the nine months ended September 30, 2023, was $1.39 billion, an increase of 30.2% from the prior year [54] - EBITDA for Q3 2023 was $90.2 million, a 1% increase compared to $89.3 million in Q3 2022 [54] - Net income for Q3 2023 was $70.6 million, up 6.9% from $66 million in the prior year [55] - EBITDA margin for Q3 2023 was 18.3%, down from 23.3% in the prior year [52] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q3 increased 29.9% year-over-year to $611.5 million, resulting in a net book-to-bill ratio of 1.24 [51] - Ending backlog as of September 30, 2023, was approximately $2.7 billion, an increase of 20.3% from the prior year [58] Market Data and Key Metrics Changes - Customer concentration: Top 5 customers represent roughly 23% and Top 10 customers represent about 29% of year-to-date total revenue [56] - Cash flow from operating activities in Q3 was $114.4 million, with net days sales outstanding at negative 42.2 days [56] Company Strategy and Development Direction - The company plans to continue investing in organic growth, with increased capital expenditures related to the expansion of its headquarters in Cincinnati [45] - The company is focusing on share repurchases opportunistically, depending on execution levels [45] Management's Comments on Operating Environment and Future Outlook - Management noted a strong business environment with record levels of RFPs and awards, despite challenges in the biotech sector [79] - The company does not expect significant margin expansion in 2024 due to ongoing wage and benefit inflation [84] Other Important Information - Full year 2023 revenue guidance is expected to be in the range of $1.87 billion to $1.89 billion, representing growth of 28.1% to 29.5% over 2022 [61] - Initial guidance for 2024 expects revenue in the range of $2.15 billion to $2.2 billion [66] Q&A Session Summary Question: Can you comment on the funding environment and its impact? - Management indicated that while there are funding challenges, they are able to find opportunities among well-funded biotech companies [71][73] Question: What is the outlook for pass-through costs? - Management noted that elevated pass-through costs are broad-based and not concentrated in any one study, with metabolic studies contributing significantly [82][86] Question: How is the company addressing the current business environment? - Management stated that they have pivoted to a different subset of small biotech with funded programs, allowing them to find opportunities despite the challenges [73] Question: What are the expectations for 2024 EBITDA margins? - Management does not expect significant margin expansion in 2024 due to ongoing inflationary pressures [84]

1.38x 1.49x 17.7% 17.6% 1.28x 1.28x 1.23x 1.23x 1.28x 1.25x 17.0% 16.7% 16.6% 16.8% 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 Net New Business Awards ($ in millions) MAKING THE COMPLEX SEAMLESS Q2 2023 – KEY FINANCIAL HIGHLIGHTS A. See the appendix for the non-GAAP reconciliation of the EBITDA calculations. B. Net income per diluted share for 2Q23 and 2Q22 excludes $0.041 million and $0.031 million, respectively, in undistributed earnings allocated to RSAs. Net income p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 ______________ ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q2 2023 Earnings Conference Call July 25, 2023 9:00 AM ET Company Participants Lauren Morris - Director, IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants David Windley - Jefferies Max Smock - William Blair Sandy Draper - Guggenheim Partners Operator Good day, ladies and gentlemen, and welcome to the Medpace's Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we wi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 _____________ ...